{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:15:07Z","timestamp":1790630107194,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.euroneuro.2017.12.006","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T09:04:50Z","timestamp":1513674290000},"page":"227-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review"],"prefix":"10.1016","volume":"28","author":[{"given":"Bel\u00e9n","family":"Arranz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Garriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemente","family":"Garc\u00eda-Rizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"San","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2017.12.006_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/070674371005501007","article-title":"Where to position clozapine: re-examining the evidence","volume":"55","author":"Agid","year":"2010","journal-title":"Can. J. Psychiatry. Rev. Can. De. Psychiatr."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40429-014-0034-7","article-title":"Pharmacotherapy of co-occurring schizophrenia and substance use disorders","volume":"1","author":"Akerman","year":"2014","journal-title":"Curr. Addict. Rep."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib3","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1176\/ajp.151.5.780b","article-title":"Decreased substance use in chronically psychotic patients treated with clozapine","volume":"151","author":"Albanese","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/15504263.2015.1113761","article-title":"Substance use in patients with first-episode psychosis: is gender relevant?","volume":"11","author":"Arranz","year":"2015","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/j.1440-1614.2006.01841.x","article-title":"Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use?","volume":"40","author":"Barnes","year":"2006","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.yfrne.2007.07.003","article-title":"Sex differences in drug abuse","volume":"29","author":"Becker","year":"2008","journal-title":"Front. Neuroendocr."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/schbul\/16.1.81","article-title":"Psychotogenic drug use and neuroleptic response","volume":"16","author":"Bowers","year":"1990","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/15504263.2011.570118","article-title":"A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia","volume":"7","author":"Brunette","year":"2011","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/schbul\/sbl003","article-title":"Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders","volume":"32","author":"Brunette","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0740-5472(97)00134-7","article-title":"Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia","volume":"15","author":"Buckley","year":"1998","journal-title":"J. Subst. Abus. Treat."},{"issue":"Suppl B","key":"10.1016\/j.euroneuro.2017.12.006_bib11","first-page":"114","article-title":"Substance abuse and clozapine treatment","volume":"55","author":"Buckley","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1176\/ajp.151.3.385","article-title":"Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy","volume":"151","author":"Buckley","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib13","first-page":"890","article-title":"Does clozapine affect smoking rates?","volume":"32","author":"Chatterton","year":"1998","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0920-9964(00)00026-8","article-title":"Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia","volume":"46","author":"Combs","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.schres.2005.02.010","article-title":"A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors","volume":"76","author":"de Leon","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.pnpbp.2005.04.031","article-title":"Does clozapine decrease smoking?","volume":"29","author":"de Leon","year":"2005","journal-title":"Progress. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/mpr.1362","article-title":"Craving for cannabis in patients with psychotic disorder, their non-affected siblings and healthy controls: psychometric analysis of the obsessive compulsive drug use scale","volume":"21","author":"Dekker","year":"2012","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/JCP.0b013e31814cfaa9","article-title":"Clozapine and amisulpride in refractory schizophrenia and alcohol dependence","volume":"27","author":"Dervaux","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/oxfordjournals.schbul.a033464","article-title":"The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia","volume":"26","author":"Drake","year":"2000","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00846549","article-title":"Measuring nicotine dependence: a review of the Fagerstrom tolerance questionnaire","volume":"12","author":"Fagerstrom","year":"1989","journal-title":"J. Behav. Med."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0376-8716(99)00114-3","article-title":"Significant interaction between clozapine and cocaine in cocaine addicts","volume":"59","author":"Farren","year":"2000","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0899-3289(88)80020-8","article-title":"A study examining the psychometric properties of the SMAST-13","volume":"1","author":"Fleming","year":"1988","journal-title":"J. Subst. Abus."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib23","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0006-3223(97)00488-5","article-title":"Clozapine and body mass change","volume":"43","author":"Frankenburg","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib24","first-page":"344","article-title":"Effects of clozapine on smoking in chronic schizophrenic outpatients","volume":"56","author":"George","year":"1995","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10673229909017206","article-title":"Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?","volume":"6","author":"Green","year":"1999","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.4088\/JCP.13m08838","article-title":"Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial","volume":"76","author":"Green","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0920-9964(02)00231-1","article-title":"Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone","volume":"60","author":"Green","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jsat.2007.01.008","article-title":"Substance abuse and schizophrenia: pharmacotherapeutic intervention","volume":"34","author":"Green","year":"2008","journal-title":"J. Subst. Abus. Treat."},{"issue":"3","key":"10.1016\/j.euroneuro.2017.12.006_bib30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/schbul\/sbu120","article-title":"The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders","volume":"41","author":"Hayes","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.drugalcdep.2008.12.010","article-title":"Reliability and validity of a short form of the marijuana craving questionnaire","volume":"102","author":"Heishman","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S2215-0366(15)00207-2","article-title":"Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study","volume":"2","author":"Hjorth\u00f8j","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0269881105051542","article-title":"Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect?","volume":"19","author":"Kalyoncu","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.addbeh.2011.09.010","article-title":"Treatment of substance abusing patients with comorbid psychiatric disorders","volume":"37","author":"Kelly","year":"2012","journal-title":"Addict. Behav."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib36","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.pnpbp.2008.01.009","article-title":"Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia","volume":"32","author":"Kim","year":"2008","journal-title":"Progress. Neuro-Psychopharmacol. Biol. psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib37","doi-asserted-by":"crossref","first-page":"e642","DOI":"10.4088\/JCP.12r08178","article-title":"Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials","volume":"74","author":"Kishi","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pnpbp.2015.10.009","article-title":"Medications between psychiatric and addictive disorders","volume":"65","author":"Lalanne","year":"2016","journal-title":"Progress. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib39","first-page":"855","article-title":"Clozapine and substance abuse in patients with schizophrenia","volume":"43","author":"Lee","year":"1998","journal-title":"Can. J. Psychiatry. Rev. Can. Psychiatr."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/0269881114527357","article-title":"The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: an fMRI study","volume":"28","author":"Machielsen","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0269881111408957","article-title":"Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine","volume":"26","author":"Machielsen","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib42","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1176\/ajp.152.6.959a","article-title":"Reduction of comorbid substance abuse with clozapine","volume":"152","author":"Marcus","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0006-3223(98)00377-1","article-title":"Smoking and therapeutic response to clozapine in patients with schizophrenia","volume":"46","author":"McEvoy","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/0006-3223(94)00365-A","article-title":"Clozapine decreases smoking in patients with chronic schizophrenia","volume":"37","author":"McEvoy","year":"1995","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib45","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/00005053-199512000-00006","article-title":"A scale for assessing the stage of substance abuse treatment in persons with severe mental illness","volume":"183","author":"McHugo","year":"1995","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005053-198001000-00006","article-title":"An improved diagnostic evaluation instrument for substance abuse patients. The addiction severity index","volume":"168","author":"McLellan","year":"1980","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2014.03.002","article-title":"Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine","volume":"155","author":"Mesholam-Gately","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib48","doi-asserted-by":"crossref","unstructured":"Meszaros, Z.S., Dimmock, J.A., Ploutz-Snyder, R.J., Abdul-Malak, Y., Leontieva, L., Canfield, K., Batki, S.L., n.d. Predictors of smoking severity in patients with schizophrenia and alcohol use disorders. The American journal on addictions 20, 462\u2013467. doi: http:\/\/dx.doi.org\/10.1111\/j.1521-0391.2011.00150.x.","DOI":"10.1111\/j.1521-0391.2011.00150.x"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib49","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib50","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0004867412443900","article-title":"The impact of alcohol and illicit drugs on people with psychosis: the second Australian National Survey of Psychosis","volume":"46","author":"Moore","year":"2012","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.psychres.2010.07.042","article-title":"Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes","volume":"186","author":"Najt","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib52","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0006-3223(97)00531-3","article-title":"Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram","volume":"44","author":"Perry","year":"1998","journal-title":"Biol. Psychiatry"},{"issue":"13","key":"10.1016\/j.euroneuro.2017.12.006_bib53","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2165\/00023210-200418130-00002","article-title":"Starting clozapine in the community: a UK perspective","volume":"18","author":"O\u00b4Brien","year":"2004","journal-title":"CNS Drugs."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib54","first-page":"121","article-title":"Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses","volume":"18","author":"Potvin","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00004850-200109000-00007","article-title":"A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics","volume":"16","author":"Procyshyn","year":"2001","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0924-977X(01)00130-4","article-title":"Concomitant clozapine reduces smoking in patients treated with risperidone","volume":"12","author":"Procyshyn","year":"2002","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.20882\/adicciones.784","article-title":"Clinical guideline for the treatment of dual pathology in the adult population","volume":"28","author":"San","year":"2016","journal-title":"Adicciones"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib58","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000104886","article-title":"Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders","volume":"13","author":"San","year":"2007","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib59","first-page":"308","article-title":"Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study","volume":"23","author":"Schnell","year":"2014","journal-title":"Am. J. Addict. \/ Am. Acad. Psychiatr. Alcohol. Addict."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib60","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lfs.2008.05.014","article-title":"Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area","volume":"83","author":"Schwieler","year":"2008","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1021\/cn400189s","article-title":"Clozapine, a fast-off-D2 antipsychotic","volume":"5","author":"Seeman","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib62","series-title":"Guiding Principles and Elements of Recovery-Oriented Systems of Care: what Do We Know From the Research?","author":"Sheedy","year":"2009"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib63","first-page":"1","article-title":"Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis","author":"Siskind","year":"2016","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib64","series-title":"Evaluating Alcohol and Drug Abuse Treatment Effectiveness","first-page":"129","article-title":"Developing a prototype for evaluating alcohol treatment effectiveness","author":"Sobell","year":"1980"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib65","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14622200210123581","article-title":"Biochemical verification of tobacco use and cessation","volume":"4","author":"SRNT Subcommittee on Biochemical Verification","year":"2002","journal-title":"Nicotine Tob. Res.: Off. J. Soc. Res. Nicotine Tob."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib66","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.schres.2007.05.007","article-title":"Effectiveness of atypical antipsychotics for substance use in schizophrenia patients","volume":"94","author":"Swanson","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib67","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.schres.2009.09.032","article-title":"Smoking expectancies and intention to quit in smokers with schizophrenia, schizoaffective disorder and non-psychiatric controls","volume":"115","author":"Tidey","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib68","first-page":"CD007253","article-title":"Interventions for smoking cessation and reduction in individuals with schizophrenia","author":"Tsoi","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib69","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1176\/ajp.156.7.1119a","article-title":"Clozapine for substance-abusing schizophrenic patients","volume":"156","author":"Tsuang","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib70","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/2045125314566808","article-title":"Clozapine prescribing in the UK: views and experience of consultant psychiatrists","volume":"5","author":"Tungaraza","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib72","doi-asserted-by":"crossref","unstructured":"Wehring, H.J., Heishman, S.J., McMahon, R.P., Liu, F., Feldman, S., Raley, H., Weiner, E., Kelly, D.L., 2017. Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia. J. Dual Diagn. 13, 36\u201342. 10.1080\/15504263.2017.1288946.","DOI":"10.1080\/15504263.2017.1288946"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib73","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-004-1940-5","article-title":"The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine","volume":"177","author":"Weiner","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib74","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1744-859X-13-7","article-title":"Antipsychotic medication and tobacco use among outpatients with schizophrenia: a cross-sectional study","volume":"13","author":"Wijesundera","year":"2014","journal-title":"Ann. General. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib75","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.pnpbp.2008.02.008","article-title":"Pharmacotherapy of schizophrenia with comorbid substance use disorder--reviewing the evidence and clinical recommendations","volume":"32","author":"Wobrock","year":"2008","journal-title":"Progress. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.12.006_bib76","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.schres.2009.04.016","article-title":"Prepulse inhibition deficits in schizophrenia are modified by smoking status","volume":"112","author":"Woznica","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib77","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JCP.0b013e31828b2575","article-title":"Do atypical antipsychotics really enhance smoking reduction more than typical ones?: the effects of antipsychotics on smoking reduction in patients with schizophrenia","volume":"33","author":"Wu","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib78","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00406-015-0636-7","article-title":"Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders","volume":"267","author":"Wu","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib79","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00005053-199410000-00017","article-title":"Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: a case report and a hypothesis","volume":"182","author":"Yovell","year":"1994","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2017.12.006_bib80","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00004714-200002000-00016","article-title":"Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey","volume":"20","author":"Zimmet","year":"2000","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17320321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17320321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:51:54Z","timestamp":1760377914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X17320321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0924977X17320321"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.12.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}